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This study used the aggregate data meta-analytic approach to determine the combined eﬀects of aerobic exercise and diet on lipids
and lipoproteins in overweight and obese adults. Twelve studies representing 859 men and women (443 intervention, 416 control)
were included. Using random-eﬀects models, statistically signiﬁcant, intervention minus control reductions were found for TC
(−12.8mg/dL, 95% CI, −19.9 to −5.7), TC:HDL-C (−0.5mg/dL, 95% CI, −0.8 to −0.1), LDL-C (−6.8mg/dL, 95% CI, −11.8 to
−1.8), and TG(−13.1mg/dL, 95% CI, −21.2 to −5.0) but not HDL-C (−0.4mg/dL, 95% CI, −2.3 to 1.6). Results remained robust
when adjusted for publication bias, deleting each study from the model once, and collapsing results for multiple groups from the
same study into one eﬀect size. These ﬁndings suggest that concurrent aerobic exercise and diet improve TC, LDL-C, TC:HDL-C,
and TG, but not HDL-C, in overweight and obese adults.
1.Introduction
Overweight and obesity is a major public health problem
worldwide. For example, the World Health Organization
reportedthattheglobalprevalenceofoverweightandobesity
in adults, deﬁned as a body mass index (BMI) ≥25kg/m2,i s
approximately 2 billion, and by the year 2015, will increase
to approximately 3 billion [1]. In the United States (US), an
estimated 68% of adults are either overweight or obese [2].
Less-than-optimal concentrations of lipids and lipoproteins,
a major risk factor for cardiovascular disease [3], are more
prevalentamongoverweightandobeseversusnormalweight
adults. For example, using data from the United States
Behavioral Risk Factor Surveillance System Survey, the age-
adjusted prevalence of elevated total cholesterol (TC) was
approximately 10% to 16% greater among overweight and
obese versus normal weight adults [4]. Aerobic exercise
combined with diet is commonly recommended for improv-
ing and maintaining optimal concentrations of lipids and
lipoproteins in overweight and obese adults [5]. However,
previous randomized controlled trials addressing the com-
binedeﬀectsofaerobicexerciseanddietsaimedatimproving
TC, high-density lipoprotein cholesterol (HDL-C), ratio of
TC:HDLC, low-density lipoprotein cholesterol (LDL-C),
and triglycerides (TG) in adults have reached conﬂicting
conclusions [6–17]. For example, using the vote-counting
approach [18], the percentage of outcomes reported as sta-
tistically signiﬁcant has been underwhelming: TC (43%),
HDL-C (8%), TC:HDL-C (43%), LDL-C (25%), TG (46%).
The between-study discrepancy in these ﬁndings may be
related to such things as age, gender, baseline lipid and
lipoprotein levels, intervention characteristics, changes in
body composition, aerobic ﬁtness, and nutrient intake.
However, reliance on the vote-counting approach can be
extremely misleading [18]. Meta-analysis is a quantitative
approach for combining the results of studies. The strengths
of meta-analysis include (1) increased power, (2) improved
estimates of eﬀect size, and (3) the potential to resolve
disagreements between studies [19]. Thus, given the afore-
mentioned conﬂicting ﬁndings, the purpose of this study2 Journal of Obesity
was to use the meta-analytic approach to determine the
combined eﬀects of aerobic exercise and diet on lipid and
lipoprotein concentrations in overweight and obese adults.
2. Methods
2.1. Data Sources. Studies for the current meta-analysis were
retrieved from a large in-house aerobic exercise and diet
database that includes 1401 citations (all references available
upon request). The initial database was developed by search-
ing nine electronic databases, (PubMed, EMBASE, CINAHL,
Cochrane Central Register of Controlled Trials, SportDis-
cus, Dissertation Abstracts International, Physiotherapy Evi-
dence Database (PEDRO), Latin American and Caribbean
Health Sciences Database (LILACS), Web of Science), cross-
referencing from retrieved studies, and expert review (SR,
WH).
Per recent PRISMA recommendations [20], the search
query used for one of the databases included in the original
search (PubMed) is shown as follows.
User Query for PubMed Search.
(“1955/01/01” [PDAT]: “2009/05/01” [PDAT]) AND
((“exercise” [MeSH Terms] OR
“exercise” [All Fields]) AND (“diet” [MeSH Terms]
OR “diet” [All Fields]) AND
(“lipids” [MeSH Terms] OR “lipids” [All Fields]) OR
(“exercise” [MeSH Terms] OR
“exercise” [All Fields]) AND (“diet” [MeSH Terms]
OR “diet” [All Fields]) AND
(“cholesterol” [MeSH Terms] OR “cholesterol” [All
Fields])) AND
(“humans” [MeSH Terms] AND Randomized Con-
trolled Trial[ptyp] AND “adult” [MeSH Terms]).
2.2.StudySelection. Theinclusioncriteriaforthisstudywere
as follows: (1) randomized trials with a comparative control
group (no intervention, usual care, attention control), (2)
aerobic exercise along with any diet considered to improve
lipids and lipoproteins (low saturated fat, caloric restriction,
etc.), (3) combined aerobic exercise and diet intervention ≥4
weeks, (4) adult humans ≥18 years of age, (5) allparticipants
considered to have a BMI ≥25kg/m2, (6) published studies,
including dissertations and Master’s theses, (7) studies
published in any language, (8) studies published between
January 1, 1955 and May 1, 2009, and (9) assessment of one
or more of the following lipids and lipoproteins: TC, HDL-
C, TC:HDL-C, non-HDL-C, LDL-C, and TG. The year
1955 was chosen as the starting point for potential inclusion
of studies since this appeared to be the ﬁrst time that an
intervention on aerobic exercise and diet had been reported
[21]. Aerobic exercise was deﬁned according to the recent
PhysicalActivityGuidelinesActivityReport,thatis,“Exercise
that primarily uses the aerobic energy-producing systems,
can improve the capacity and eﬃciency of these systems, and
is eﬀective for improving cardiorespiratory endurance” [22].
Any studies not meeting all the criteria above were excluded
from the study. All studies were selected by the ﬁrst two
authors. Discrepancies were resolved by consensus.
2.3. Data Abstraction. Electronic codebooks that could
recordupto205itemsperstudyweredevelopedpriortodata
abstraction. The major categories that were coded included
(1) study characteristics, (2) participant characteristics, (3)
aerobic exercise and diet characteristics, and (4) changes
in primary and secondary outcomes. The ﬁrst two authors
coded all studies independent of each other and then
reviewed each item for accuracy and consistency. Disagree-
ments were discussed until agreement could be reached.
Because of the lack of empirical evidence [23, 24],
including validity [25, 26], to support the use of quality
scales, the risk of bias assessment tool recently recommended
by the Cochrane Collaboration was used [27]. Brieﬂy, this
instrument assesses bias across six domains: (1) sequence
generation,(2)allocationconcealment,(3)blindingtogroup
assignment, (4) incomplete outcome data, (5) selective
outcome reporting, and (6) other potential bias [27]. Each
domain is categorized as having either a high, low, or unclear
risk of bias [27]. Assessment for the potential risk of bias was
limited to the study’s primary outcomes. Given the methods
used to assess lipids and lipoproteins versus a more qualita-
tive measure such as self-reported quality of life, all studies
were considered to be at a low risk of bias for blinding. Other
potential bias included whether participants had been taking
part in a regular exercise program, as deﬁned by the study
authors, prior to study enrollment. The ﬁrst two au-thors
conducted all bias assessments independent of each other
and then met and reviewed every item for agreement. Dis-
agreements were discussed until consensus could be reached.
2.4. Statistical Analysis
2.4.1. Calculation of Eﬀect Sizes from Each Study. The prima-
ry outcomes of interest were TC, HDL-C, TC:HDL-C, non-
HDL-C,LDL-C,andTG.Theoriginalmetric(milligramsper
deciliter)waschosenastheeﬀectsize(ES)foranalysis.While
somewhat arbitrary, at least 5 ESs per variable were required
in order to be included in the meta-analysis. The ES for each
lipidandlipoprotein variableforeachgroupfromeachstudy
were calculated by subtracting the change score diﬀerence in
the aerobic exercise and diet group from the change score
diﬀerence in the control group. The variance for each ES was
calculated from the pooled standard deviations of change
scores in the intervention (aerobic exercise and diet) and
control groups. If change score standard deviations were not
available,theywerecalculatedfrom95%conﬁdenceintervals
or before and after standard deviation values according to
previously developed procedures [28]. Each ES was then
weighted by the inverse of its variance. Missing primary
outcome data were requested and received from the authors
of two studies [7, 8].
Secondary outcomes included changes in body
weight, BMI in kg/m2, maximum oxygen consumption
(VO2maxmL·kg−1·min−1), and intake of kilocalories,Journal of Obesity 3
carbohydrates, total fat, saturated fat, and cholesterol. A
lack of data were available for the inclusion of non-HDL-C
(dispersion statistics), percent body fat, lean body mass,
waist circumference, energy expenditure, protein, ﬁber, and
transfat.
2.4.2. Pooled Estimates of ESs for Primary and Secondary
Outcomes. Random-eﬀects, method of moments models
that incorporates heterogeneity in the analysis, were used to
pool primary and secondary outcomes [29]. The sole focus
on random-eﬀects models is based on the fact that random-
eﬀects models assume that the true eﬀect size varies across
studies whileﬁxed-eﬀectsmodels assumeone trueeﬀectsize,
the latter of which is almost never the case [30]. Multiple
groups from the same study were analyzed separately as well
as after collapsing groups so that one ES represented each
study. Two-tailed 95% conﬁdence intervals that did not cross
zerowereconsideredtobestatisticallysigniﬁcant.Eﬀectsizes
with standardized residuals greater than 3 were deleted from
the ﬁnal model.
Heterogeneity was assessed using Cochran’s Q statistic
and an alpha value for statistical signiﬁcance of 0.10 [31].
Between-study inconsistency of ES was examined using an
extension of the Q statistic, I2 [32]. Generally, I2 values of
25% to <50%, 50% to <75%, and ≥75% are considered to
representsmall,medium,andlargeamountsofinconsistency
[32].
Publicationbiaswasexamined using thedataimputation
approach of Duval and Tweedie [33]. In addition, the
inﬂuence of each study on the overall results was examined
by deleting each study from the model once. Cumulative
meta-analysis, ranked by year, was used to examine results
over time [34] while 95% prediction intervals were used to
determine treatment eﬀects in a new trial [35]. Simple, ran-
domeﬀectsmetaregression(method-of-momentsapproach)
was conducted to examine the association between changes
in lipids and lipoproteins and age, gender, baseline lipid and
lipoprotein levels, length of the intervention in weeks and
changes in body weight, BMI, VO2max in mL·kg−1·min−1,
kilocalories, total fat, saturated fat, and cholesterol. In addi-
tion, meta-regression was conducted in order to examine the
relationship between gender and changes in body weight,
total kilocalories, total fat, saturated fat and cholesterol
consumed. Nonoverlapping 95% conﬁdence intervals for the
slope (β1) were considered statistically signiﬁcant. With the
exception of the length of the intervention, we were unable
toconductanytypeofanalyseswithrespecttodose-response
associations.
Descriptive statisticsweregeneratedusingPASW,version
18.0, reliability using Excel 2007 and all meta-analytic anal-
yses using Comprehensive Meta-Analysis, version 2.2. Data
arereportedasmean ±standarddeviation(X±SD),medians
(Mdn), percentages (%) and 95% conﬁdence intervals (95%
CI).
3. Results
3.1. Study Characteristics. Twelve studies representing up to
28 groups (14 intervention, 14 control) and 859 men and
women (443 intervention, 416 control) were available for
pooling[6–17].Aﬂowchartthatdescribesthesearchprocess
isshowninFigure 1whileageneraldescriptionofthestudies
is shown in Table 1. The number of groups was greater than
the number of studies because two studies reported data
partitioned by gender [10, 17]. Dropout rates for the 11
groups in which data were available ranged from 0% to
63.6%intheinterventiongroups(X ±SD,13.5 ±17.7,Mdn,
9)and0%to40%inthecontrolgroups(X ±SD,13.3 ±13.3,
Mdn,9).Littleinformationwasprovidedforthereasonswhy
participants dropped out of the studies. The ﬁnal number of
participants in which data were pooled ranged from 4 to 137
in the exercise and diet groups (X ± SD, 32 ± 32, Mdn, 23)
and 6 to 140 in the control groups (X ± SD, 30 ± 33, Mdn,
23).Nineof12studies(75%)reportedreceivingsometypeof
external funding [6–8, 10, 13–17]. Eleven of the 12 included
studies (91.7%) were published in journals [6–11, 13–17]
while 1 was a dissertation [12]. All studies were published
in the English language between 1986 and 2006 [6–17]. With
respect to statistical analysis, all studies appeared to use the
per-protocol approach in the analysis of their data [6–17].
Five of 12 studies (41.7%) reported some type of matching
procedure [6, 8, 13, 14, 17]. This included stratiﬁcation by
either bodyweight [8], race (African-American and other)
[14], sex [17], sex and degree of insulin sensitivity [13], or
type of medication (insulin or oral agents and diet therapy)
[6]. None of the studies used a crossover design [6–17].
3.2. Risk of Bias Assessment. Overall results for risk of bias
are shown in Figure 2. As can be seen, all studies appeared to
use appropriate procedures for sequence generation [6–17],
but only one reported an acceptable process for allocation
concealment [14]. Given the methods used for the assess-
ment oflipid andlipoprotein concentrations,allstudies were
considered to be at a low risk of bias for blinding [6–17]. Less
than half the studies were considered to be at a low risk of
bias with respect to incomplete data [8, 9, 11, 14]. Given the
absence of a study protocol identiﬁcation number, the risk
of bias for incomplete outcome reporting was determined
t ob eu n c l e a ra c r o s sa l ls t u d i e s[ 6–17]. The majority of
studies (66.7%) were considered to be at a low risk of bias
with regards to participants engaging in a regular exercise
program prior to study enrollment [7–10, 12, 13, 15, 17].
3.3. Participant Characteristics. A description of the charac-
teristics of participants for each study is shown in Table 1
while a group description is shown in Table 2. Seven studies
included men and women [6, 8, 10, 13, 14, 16, 17]w i t h
two reporting data separately according to gender [10, 17].
Another four studies were limited to women [9, 11, 12, 15]
while one was limited to men [7]. The number of men
and women could not be calculated because of missing data
from some studies. For the ﬁve studies reporting data on
race/ethnicity [6, 9, 11, 13, 14], one each reported that
participants were either African-American [6], Caucasian
[13], Japanese [11], or Latino (90% Mexican-American and
10% Mexican) [9]. Another study reported that 68% of the
participantsintheinterventiongroupand57%inthecontrol
group were black [14].4 Journal of Obesity
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Figure 1: Flow diagram for the selection of studies.
Information on prescription medication use was re-
ported by six studies [6, 7, 9, 13, 14, 17]. Three reported
that all participants were taking some type of prescription
drugduring thestudy [6,7,14],one reported that some were
taking medication [13], while another reported that with
the exception of hormone replacement therapy, none were
taking medication [9]. Another study reported that none
of the participants were taking any medications known to
aﬀect blood pressure or lipid metabolism [17]. Prescription
druguseincludedlipidmedications,diuretics,beta-blockers,
alpha-blockers, calcium channel blockers and angiotensin
receptor blockers [14], calcium antagonists, beta-blockers,
diuretics, and angiotensin converting enzyme inhibitors [7]
or insulin and oral agents [6]. One study reported that
participants were allowed to continue their medication use
during the study as long as they had been taking them for
at least six months and were unlikely to change their intake
[13]. Two studies reported that none of the women wereJournal of Obesity 7
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Figure 2: Risk of bias assessment.
Table 2: Initial characteristics of participants.
Variable
Exercise Control
# X ±SD Range Mdn # X ±SD Range Mdn
Age (years) 13 46.3 ± 8.6 34–62 46.0 13 45.6 ± 8.7 33–61 45
Body weight (kg) 12 87.5 ± 34.9 66–99 92.39 12 88.2 ± 12.1 66–103 91.3
BMI (kg·m2) 8 31.8 ± 3.2 27–36 32.7 8 32.4 ± 3.9 26–37 33.7
VO2max(mL·kg−1·min−1) 7 28.5 ± 6.2 20–36 29.4 7 28.5 ± 6.3 21–38 29.0
Kilocalories (total) 8 2018 ± 319 1488–2616 1999 8 1950 ± 353 1398–2616 1922
Carbohydrates (%) 5 49.6 ±1.8 48–53 49.0 5 49.7 ± 2.8 47–54 48.4
Total fat (%) 8 32.4 ± 3.7 28–38 32 8 32.7 ± 3.7 27–38 32.6
Saturated fat (%) 5 12.6 ± 1.8 10–14 13.6 5 12.4 ± 2.2 9–14 13.6
Cholesterol (mg) 5 318 ± 61 248–400 296 5 280 ± 78 197–400 284
TC (mg/dL) 14 212.5 ± 24.7 188–271 202.2 14 204.3 ± 16.4 185–238 201.3
HDL-C (mg/dL) 13 48.8 ± 6.5 38–58 49.0 13 48.0 ± 6.6 38–58 49.9
TC:HDL-C 5 4.8 ± 0.6 4.1–5.3 4.9 5 4.8 ± 0.5 4.1–5.2 4.9
LDL-C (mg/dL) 8 133.4 ± 17.1 115–172 127.0 8 131.1 ± 12.9 117–156 126.5
TG (mg/dL) 12 103.7 ± 55.0 33–224 84.9 12 102.7 ± 46.2 33–166 102.8
Notes. #, number of groups in which data were available. With the exception of age, data limited to those in which change outcome results could be calculated.
Mdn, median; BMI, body mass index; VO2max, maximum oxygen consumption; mg, milligrams; TC, total cholesterol; HDL-C, high-density lipoprotein
cholesterol; TC:HDL-C, ratio of TC to HDL; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides. To convert TC, HDL-C and LDL-C from mg/dL
to mmol, divide by 38.46, to convert TG from mg/dL to mmol, divide by 87.72. Insuﬃcient data (<5) reported for protein, polyunsaturated fat, saturated fat,
and trans-fat intake as well as non-HDL-C.
taking any type of hormone replacement therapy during the
study [12, 17] while another reported that some were taking
hormone replacement therapy [9].
Data on cigarette smoking was reported by seven studies
[6–8, 12, 14, 15, 17] with four reporting that none of the
participants smoked [8, 12, 15, 17] and three reporting that
some smoked [6, 7, 14]. For alcohol consumption, one study
reported that none of the participants consumed alcohol
[10] while two others reported that some did [13, 14]. Eight
studies reported that participants were sedentary prior to
study enrollment [7–10, 12, 13, 15, 17]. Little information
was provided on whether the participants changed their
level of physical activity beyond that prescribed to the
intervention group. One study did report a decrease in
physical activity among participants in the control group
[6]. For those studies that included women, ﬁve included
both pre- and postmenopausal females [8, 13–16], two were
limited to premenopausal women [12, 17], and one was
limited to postmenopausal women [6]. At least 10 of the 12
studies included some participants who were hyperlipidemic
[6, 7, 9–12, 14–17]. Seven studies reported that none of the
participants had type 2 diabetes [8, 10, 13–16] while one
reported that all did [6]. Eight of the studies reported that
none of the participants had Type 1 diabetes [6–8, 10, 13–
16]. In relation to hypertension, two studies reported that
all participants were hypertensive [7, 14], one reported that
some were [6], and one reported that none were [10]. Five
studies reported that none of the participants had a previous
history of cardiovascular disease [7, 8, 10, 14, 15], one
reported no previous history of stroke [7], another reported
no history of metabolic syndrome [8], and another reported
no previous history of cancer [15].8 Journal of Obesity
3.4. Aerobic Exercise and Diet Interventions
3.4.1. Aerobic Exercise. A description of the aerobic exercise
component of the intervention is shown in Table 1.I n t e r -
vention length ranged from 8 to 208 weeks (X ± SD, 39 +
56, Mdn, 12) while the between-group frequency of aerobic
training ranged from 2 to 6 sessions per week (X ±SD, 4 + 1,
Mdn, 3) [6–17]. Within-group frequency of training ranged
from 1 to 7 sessions per week for the three studies in which
information was available [6, 8, 9]. For the 6 studies and 7
groups in which data were provided [6, 8, 10–12, 15], the
mean between-group duration of training ranged from 20 to
50 minutes per session (X ± SD, 35 ± 10, Mdn, 30) while
the within-group duration ranged from 15 to 60 minutes for
the 7 studies and 8 groups that reported such [8, 9, 13–17].
Within-group intensity of training ranged from 50% to 90%
ofmaximumheartrate(MHR)forthe6studiesand7groups
that reported data [7, 8, 13–15, 17]. Insuﬃcient data were
provided to calculate between-group intensity of training.
Between-group total minutes of training ranged from 60 to
228 minutes per week (X ± SD, 142 ± 69, Mdn, 150) for the
6 studies and 7 groups from which data could be calculated
[6, 8, 10–12, 15]. The most common types of activities were
walking followed by jogging and cycling. Between-group
compliance, deﬁned as the percentage of exercise sessions
attended, ranged from 38% to 98% for the 5 studies in which
adequate data were provided (X ± SD, 78 ± 24, Mdn, 86)
[8, 12, 14–16]. Ten studies representing 12 groups reported
exercise data (frequency, intensity, duration) based on what
was prescribed versus completed [6, 7, 9–11, 13–17] while
twoothersreportedwhatwasactuallycompleted[8,12].Five
studies comprising 7 groups reported that exercise sessions
were supervised [8, 10, 12, 14, 17], 1 reported that exercise
was unsupervised [11] while the remaining 6 included both
supervised and unsupervised sessions [6, 7, 9, 13, 15, 16].
3.4.2. Diet. A description of the diet interventions employed
is shown in Table 1. Two studies representing 3 groups
used the National Cholesterol Education Program (NCEP)
Step 1 diet [15, 17] while two others used either the
American Heart Association (AHA) Step 1 diet [8] or a diet
based on previous recommendations from the California
Dietetics Association [9]. Diets included caloric restriction
only and/or modiﬁcation of other dietary components (fat,
saturated fat, ﬁber, etc.). Ten studies representing 12 groups
reportedweightlossasagoalforallparticipants[6,8–12,14–
17] while another reported weight loss as a goal for some
participants [13]. Another study reported that weight loss
w a sn o tag o a l[ 7].
3.5. Assessment of Primary Outcomes. Results for lipid and
lipoprotein assessment procedures are shown in Table 1.
Nine of 12 studies reported that participants fasted prior
to the assessment of lipids and lipoproteins [6–8, 10, 12–
14, 16, 17] with fasting occurring for at least 12 hours [6–
8, 10, 12, 17]. Since the three other studies did not report this
information, the investigative team was unable to determine
whether the participants fasted [9, 11, 15]. For the 8 studies
in which data were available, all reported that assessment
took place in the morning [6–8, 10, 12–14, 17]. Three studies
reported that exercise was avoided for at least 12 hours prior
to lipid assessment [8, 12, 17]. One study reported that lipid
and lipoprotein assessment took place between August and
April [12].
3.6. Assessment of Secondary Outcomes. For those studies
in which data were available, bodyweight was assessed
using either standard or electronic scales [6, 8, 9, 11–
14, 16, 17]. Maximum oxygen consumption (VO2max in
mL·kg−1·min−1) was measured using either a graded, maxi-
mal [10, 17], or submaximal [13] treadmill test or estimated
from a walk test [9, 16].
For those studies that reported data, a variety of methods
were used for assessing nutrient intake. These included a 1-
week food frequency questionnaire [6], 3-day food record
[8, 10], 3-day food record and 24 hour recall [15], 3-
day food record and block food frequency questionnaire
[16], 4-day food record [13] self-reported and interviewer
administered 7-day food records [17] and a semiquantitative
food frequency questionnaire [11].
3.7. Pooled Estimates of ES
3.7.1. Primary Outcomes. Overall group-level changes in
lipid and lipoprotein concentrations are shown in Table 3
and Figures 3, 4, 5, 6,a n d7. One outlier for changes in
TC was deleted from the model [9]. Statistically signiﬁcant
intervention minus control improvements were found for
TC, TC:HDL-C, LDL-C, and TG, but not for HDL-C.
Changes were equivalent to relative improvements of 6.0%,
10.4%, 5.1%, and 12.6%, respectively, for TC, TC:HDL-
C, LDL-C, and TG. A nonsigniﬁcant decrease of 0.8%
was observed for HDL-C. A medium to large amount
of heterogeneity was found for all lipid and lipoprotein
outcomes and all prediction intervals encompassed zero (0).
When adjusted for publication bias, changes in TG remained
signiﬁcant (X, −10.3mg/dL, 95% CI, −18.9, −1.8). No
adjustment for publication bias was needed for any other
lipid and lipoprotein outcome. With each study deleted from
the model once, the signiﬁcance/nonsigniﬁcance of results
did not change. Cumulative meta-analysis, ranked by year,
demonstrated that changes have remained signiﬁcant since
1989 for TC, 1991 for TC:HDL-C and TG, 2002 for LDL-C
whilechangesinHDL-Chavecontinuedtobenonsigniﬁcant
since the ﬁrst included study in 1986. The direction of results
did not change when studies with multiple groups were col-
lapsed so that only one ES represented each study (Table 4).
However, the amount of heterogeneity was reduced to a
nonsigniﬁcant value for TC:HDL-C.
Meta-regression results are shown in Table 5.F o rT C ,
shorter interventions and greater decreases in body weight
and BMI were associated with larger reductions in TC.
Greater increases in HDL-C were associated with larger
increases in VO2max and greater decreases in kilocalories.
For TC:HDL-C, larger decreases were associated with
being male, having higher baseline values of TC:HDL-
C and greater reductions in bodyweight and kilocalories.
Greater reductions in LDL-C were correlated with shorterJournal of Obesity 9
Point Lower  Upper 
estimate limit limit
Agurs-Collins et al. (1997) None
Anderssen et al. (2005) None
Arciero et al. (2006) None
Hagan et al. (1986) Men
Hagan et al. (1986) Women
Hirose et al. (2002) None
Hopewell (1989) None
McAuley et al. (2002) None
Miller et al. (2002) None
Nieman et al. (2002) None
Wing et al. (1998) None
Wood et al. (1991) Men
Wood et al. (1991) Women
0.00 30.00 60.00
Favors treatment  Favors control
−60.00 −30.00
Study name Subgroup within study Statistics for each study Point estimate and 95% CI
−9.1
2.2
−6.0
−36.0
−10.0
−12.4
−9.7
−15.5
−25.0
−24.0
−3.5
−9.3
−9.7
−12.8
−33.0
−1.5
−19.2
−49.9
−29.0
−28.2
−26.6
−26.0
−37.0
−33.8
−15.0
−22.3
−18.0
−19.9
14.8
5.8
7.2
−22.1
9.0
3.4
7.2
−4.9
−13.0
−14.2
8.1
3.7
−1.3
−5.7
Figure 3: Forest plot for changes in TC (mg/dL).
Study name Subgroup within study Statistics for each study Point estimate and 95% CI
Point Lower Upper
estimate limit limit
Agurs-Collins et al. (1997) None 0.0 3.7
Anderssen et al. (2005) None 1.1
Arciero et al. (2006) None −1.0 −6.5 4.5
Hagan et al. (1986) Men 3.0 0.4 5.6
Hagan et al. (1986) Women −2.0 −6.5 2.5
Hirose et al. (2002) None −2.1 −6.7 2.5
Hopewell (1989) None −0.5 −5.3 4.3
McAuley et al. (2002) None −5.0 −7.8 −2.2
Miller et al. (2002) None −5.0 −8.0 −2.0
Nieman et al. (2002) None −2.3 −5.2 0.5
Wing et al. (1998) None −0.8 −5.1 3.5
Wood et al. (1991) Men 7.3 4.5 10.2
Wood et al. (1991) Women 2.7 −0.8 6.3
−0.4 −2.3 1.6
0.00 5.00 10.00
Favors control Favors treatment
−10.00 −5.00
−3.7
−0.2 −1.6
Figure 4: Forest plot for changes in HDL-C (mg/dL).
interventions as well as larger decreases in bodyweight
and BMI. Larger reductions in TG were associated with
younger age, higher initial TG levels, and greater decreases
in bodyweight. No other statistically signiﬁcant associations
were observed.
3.7.2. Secondary Outcomes. Overall group-level changes for
body weight, BMI, cardiorespiratory ﬁtness, and diet out-
comes are shown in Table 3. Statistically signiﬁcant in-
tervention minus control group improvements were found
for bodyweight, BMI, VO2max in mL·kg−1·min−1, kilocal-
ories, carbohydrates, total fat, saturated fat, and choles-
terol intake. Changes were equivalent to relative improve-
ments of 6.1%, 4.4%, 15.9%, 18.9%, 5.7%, 11.7%, 26.8%,
and 41.6%, respectively, for bodyweight, BMI, VO2max
in mL·kg−1·min−1, kilocalories, carbohydrates, total fat,
saturated fat, and cholesterol intake. A small amount of
heterogeneity was found for changes in BMI, kilocalories,
and cholesterol intake while a large amount was observed
for body weight, VO2max in mL·kg−1·min−1, carbohydrates,
total fat and saturated fat intake. Nonoverlapping predic-
tion intervals for estimating what results could have been
expected if a new trial was conducted were observed for
BMI, kilocalories and cholesterol intake. Prediction intervals10 Journal of Obesity
Study name Subgroup within study Statistics for each study Point estimate and 95% CI
Point Lower  Upper 
estimate limit limit
Agurs-Collins et al. (1997) None
Arciero et al. (2006) None
Hagan et al. (1986) Men
Hagan et al. (1986) Women
Miller et al. (2002) None
Nieman et al. (2002) None
Wood et al. (1991) Men
Wood et al. (1991) Women
0.00 1.00 2.00
Favors treatment Favors control
−0.30
−0.10
−1.40
0.10
−0.23
−0.39
−1.05
−0.34
−0.49
−1.10
−0.69
−1.86
−0.45
−0.74
−0.75
−1.27
−0.56
−0.85
0.50
0.49
−0.94
0.65
0.28
−0.03
−0.83
−0.12
−0.14
−2.00 −1.00
Figure 5: Forest plot for changes in TC:HDLC.
Study name Subgroup within study Statistics for each study
Point Lower Upper
estimate limit limit
Anderssen et al. (2005) None 1.1 −2.2 4.4
Arciero et al. (2006) None −10.0 −23.1 3.1
Hagan et al. (1986) Men −24.0 −36.8 −11.2
Hagan et al. (1986) Women 1.0 −16.0 18.0
Hopewell (1989) None −10.1 −23.0 2.8
McAuley et al. (2002) None -3.9 −13.1 5.3
Miller et al. (2002) None −18.0 −30.0 −6.0
Nieman et al. (2002) None −13.5 −21.7 −5.4
Wing et al. (1998) None 3.5 −5.9 12.9
Wood et al. (1991) Men −2.7 −14.5 9.1
Wood et al. (1991) Women −10.1 −17.4 −2.7
−6.8 −11.8 −1.8
−40.00 −20.00 0.00 20.00 40.00
Favors treatment Favors control 
Point estimate and 95% CI
Figure 6: Forest plot for changes in LDL-C (mg/dL).
for all other secondary outcomes included zero (0). No
adjustment for publication bias was needed for any sec-
ondary outcomes. With each study deleted from the model
once, results remained signiﬁcant for body weight, BMI,
relative VO2max, kilocalories, total fat, saturated fat, and
cholesterol but not for carbohydrates. Cumulative meta-
analysis, ranked by year, demonstrated that changes have
remained signiﬁcant since 1986 for body weight and VO2max
in mL·kg−1·min−1, 1991 for kilocalorie and cholesterol
intake, 1994 for BMI, 2002 for total and saturated fat,
and 2005 for carbohydrates. When studies with multiple
groups were collapsed so that only one ES represented each
study, overall changes as well as heterogeneity and prediction
intervals did not change signiﬁcantly for any of the outcomes
(Table 4). Meta-regression results revealed no statistically
signiﬁcant association between gender and changes in body
weight, (β1, 1.0, 95% CI, −6.9, 8.8), kilocalories (β1, 168,
95% CI, −176, 513), total fat (β1,0 . 2 ,9 5 %C I ,−9.3, 9.7), or
saturated fat (β1, 0.2, 95% CI, −9.3, 9.7). Greater reductions
in cholesterol intake were associated with being male (β1,
77.2, 95% CI, 5.2, 149.2).
4. Discussion
The current ﬁndings suggest that concurrent aerobic exercise
and diet are associated with improvements in TC, TC:HDL-
C, LDL-C, and TG, but not HDL-C in overweight and
obese adults. Given the low baseline levels, the decreases
observed for TG may be especially noteworthy. The lack of
increase in HDL-C, despite an increase in aerobic capacity,
may have been the result of decreases in total fat intake and
weight loss. However, this would need to be tested in a large,
well-designed, randomized controlled trial before any ﬁrm
conclusions could be drawn.Journal of Obesity 11
Study name Subgroup within study Statistics for each study
Point Lower Upper
estimate limit limit
Agurs-Collins et al. (1997) None −12.8 −63.7 38.1
Anderssen et al. (2005) None −0.3 −5.3 4.7
Arciero et al. (2006) None 20.0 −17.2 57.2
Hagan et al. (1986) Men −80.0 −119.5 −40.5
Hagan et al. (1986) Women −43.0 −66.3 −19.7
Hirose et al. (2002) None −61.2 −136.9 14.5
Hopewell (1989) None 3.0 −25.4 31.4
McAuley et al. (2002) None −2.3 −9.1 4.5
Miller et al. (2002) None 7.0 −10.0 24.0
Nieman et al. (2002) None −18.9 −27.3 −10.6
Wing et al. (1998) None −30.9 −54.6 −7.2
Wood et al. (1991) Men −25.5 −37.6 −13.4
Wood et al. (1991) Women −5.8 −11.2 −0.4
−13.1 −21.3 −5.0
−150.00 −75.00 0.00 75.00 150.00
Favors treatment Favors control
Point estimate and 95% CI
Figure 7: Forest plot for changes in TG (mg/dL).
Table 3: Changes in primary and secondary outcomes (group level).
Variable Studies (#) Participants (#) ES (#) X (95% CI) Q(P) I2 (%) 95% PI
Primary outcomes
TC (mg/dL) 11 820 13 −12.8 (−19.9, −5.7)∗ 65.2 (<0.001)∗ 81.6 −38.6, 13.1
HDL-C (mg/dL) 11 820 13 −0.4 (−2.3, 1.6) 60.6 (<0.001)∗ 80.2 −7.6, 6.8
TC:HDL-C 6 383 8 −0.5 (−0.8, −0.1)∗ 46.6 (<0.001)∗ 85.0 −1.7, 0.7
LDL-C (mg/dL) 10 783 12 −6.8 (−11.8, −1.8)∗ 36.8 (<0.001)∗ 70.0 −23.3, 9.7
TG (mg/dL) 11 820 13 −13.1 (−21.3, −5.0)∗ 59.2 (<0.001)∗ 79.7 −39.1, 12.9
Secondary outcomes
Body weight (kg) 10 423 12 −5.2 (−7.3, −3.0)∗ 134.2 (<0.001)∗ 91.8 −13.3, 3.0
BMI (kg/m2) 8 197 8 −1.4 (−1.7, −1.0)∗ 10.7 (0.2) 34.4 −2.2, −0.53∗
VO2max(mL·kg−1·min−1) 5 182 7 4.8 (2.0, 7.6)∗ 123.9 (<0.001)∗ 95.2 −5.3, 14.9
Kilocalories (total) 6 389 7 −417 (−515, −320)∗ 7.7 (0.3) 21.6 −619, −216∗
Carbohydrates (%) 5 240 5 2.8 (0.8, 4.7)∗ 88.1 (<0.001)∗ 95.5 −4.3, 9.9
Total fat (%) 7 343 8 −4.1 (−6.3, −1.8)∗ 286.2 (<0.001)∗ 97.6 −12.0, 3.9
Saturated fat (%) 4 160 5 −6.2 (−5.4, −0.9)∗ 246.1 (<0.001)∗ 98.4 −13.9, 6.9
Cholesterol (mg) 4 153 5 −130 (−165, −96)∗ 5.8 (0.2) 31.6 −221, −40∗
Notes. ES, eﬀect sizes; #, number for which data were available; X (95% CI), mean and 95% conﬁdence interval; Q(P), Cochran’s Q statistic for heterogeneity
and alpha value; I2 (%), percent inconsistency statistic; 95% PI, 95% prediction intervals for a new study; ∗, statistically signiﬁcant; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; TC:HDL-C, TC:HDL-C ratio; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BMI, body mass
index; VO2max, maximum oxygen consumption; %, percentage of total kilocalorie intake. To convert TC, HDL-C, and LDL-C from mg/dL to mmol, divide
by 38.46; to convert TG from mg/dL to mmol, divide by 87.72.
Improvements remained robust when each study was
deleted from the model once. In addition, results have been
statistically signiﬁcant since at least 2002. Furthermore, these
ﬁndings appear to be more pronounced than those achieved
with aerobic exercise or diet alone. For example, previous
meta-analytic work addressing the independent eﬀects of
aerobic exercise on lipid and lipoprotein concentrations in
overweight and obese adults reported statistically signiﬁcant
decreases in TG but not TC, HDL-C or LDL-C after
sensitivity analyses were applied [36]. Another meta-analysis
that examined the eﬀects of cholesterol-lowering diets on TC
alone reported a statistically signiﬁcant reduction of 5.7%
[37]. This compares to the approximate 8.2% reduction
observed in the current investigation. However, this prior
meta-analysis did not appear to be limited to overweight and
obese adults and excluded trials aimed primarily at lowering
body weight [37].
The ﬁndings of the current investigation appear to be
clinically important. Using data from previous research, the
improvements in lipids and lipoproteins observed in the12 Journal of Obesity
Table 4: Changes in primary and secondary outcomes (study level).
Variable Studies (#) Participants (#) ES (#) X (95% CI) Q(P) I2 (%) 95% PI
Primary outcomes
TC (mg/dL) 11 820 11 −12.6 (−20.1, −5.1)∗ 60.5 (<0.001)∗ 83.5 −38.8, 13.6
HDL-C (mg/dL) 11 820 11 −0.8 (−2.8, 1.2) 53.0 (<0.001)∗ 81.1 −21.3, 19.7
TC:HDL-C 6 383 6 −0.5 (−0.7, −0.3)∗ 9.1 (0.11) 45.0 −1.1, 0.1
LDL-C (mg/dL) 10 783 10 −6.8 (−11.8, −1.8)∗ 30.4 (<0.001)∗ 70.4 −22.6, 9.1
TG (mg/dL) 11 820 11 −10.6 (−18.8, −2.4)∗ 48.1 (<0.001)∗ 79.2 −35.4, 14.3
Secondary outcomes
Body weight (kg) 10 423 10 −4.3 (−6.6, −2.0)∗ 125.3 (<0.001)∗ 92.8 −12.7, 4.0
BMI (kg/m2) 8 197 8 −1.4 (−1.7, −1.0)∗ 10.7 (0.2) 34.4 −2.2, −0.53∗
VO2max(mL·kg−1·min−1) 5 182 5 3.6 (0.3, 7.0)∗ 121.4 (<0.001)∗ 96.7 −9.4, 16.6
Kilocalories (total) 6 389 6 −405 (−512, −298)∗ 7.3 (0.2) 32.0 −660, −150∗
Carbohydrates (%) 5 240 5 2.8 (0.8, 4.7)∗ 88.1 (<0.001)∗ 95.5 −4.3, 9.9
Total fat (%) 7 343 7 −3.5 (−5.8, −1.1)∗ 284.7 (<0.001)∗ 97.9 −11.9, 4.9
Saturated fat (%) 4 160 4 −3.5 (−6.4, −0.5)∗ 245.8 (<0.001)∗ 98.8 −17.9, 11.0
Cholesterol (mg) 4 153 4 −127 (−153, −101)∗ 1.1 (0.8) 0 −185, −69∗
Notes. ES, eﬀect sizes; #, number for which data were available; X (95% CI), mean and 95% conﬁdence interval; Q(P), Cochran’s Q statistic for heterogeneity
and alpha value; I2 (%), percent inconsistency statistic; 95% PI, 95% prediction intervals for a new study; ∗, statistically signiﬁcant; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; TC:HDL-C, TC:HDL-C ratio; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; BMI, body mass
index; VO2max, maximum oxygen consumption; %, percentage of total kilocalorie intake. To convert TC, HDL-C, and LDL-C from mg/dL to mmol, divide
by 38.46; to convert TG from mg/dL to mmol, divide by 87.7.
current meta-analysis would be equivalent to relative risk
reductions in all-cause and coronary heart disease mortality
of 5.7% and 8.0%, respectively, for TC and 2.8% and 5.0%
for LDL-C [38] while reductions in TC:HDL-C would
equate to a an approximate 12.4% decrease in the relative
risk of mortality from ischemic heart disease [39]. For TG,
the observed decreases would be equivalent to a relative
risk reduction of 6.4% in coronary heart disease mortality
[40]. The decreases observed for LDL-C may be especially
important given that LDL-C is currently the primary target
of lipid-lowering therapy in adults [5].
Although the overall results of the current meta-analysis
suggest that a combined program of aerobic exercise and
diet improves TC, TC:HDL-C, LDL, and TG, a moderate
to large amount of heterogeneity and inconsistency was
observed for all lipid and lipoprotein outcomes. Given these
ﬁndingsanddespitethefactthatarandom-eﬀectsmodelthat
incorporates heterogeneity into the analysis was used, the
generalization of results may not be appropriate [27]. How-
ever, the use of such statistics to decide what comprises true
heterogeneity and inconsistency is rather arbitrary in nature,
a n dt h u s ,s h o u l db ev i e w e dw i t hc a u t i o n[ 41]. Another
issue has to do with the fact that all prediction intervals
for estimating the expected results of a new trial included
zero for all lipid and lipoprotein outcomes. However, these
valuesshouldnotbeconfusedwithconﬁdenceintervalssince
prediction intervals are based on a random mean eﬀect while
conﬁdence intervals are not [35].
Meta-regression analyses resulted in several statisti-
cally signiﬁcant associations, most notably, the association
between decreases in bodyweight with reductions in TC,
TC:HDL-C, LDL-C, and TG. However, while an important
ﬁrst step, all reported meta-regression analyses should be
viewed with caution. For example, the investigative team
was unable to conduct any type of multiple meta-regression
analyses because of the small number of ESs as well as
missing data for diﬀerent variables from diﬀerent studies,
a common occurrence in meta-analysis. Consequently, the
potential for confounding exists. In addition, because of the
large number of statistical tests conducted, one or more of
the statistically signiﬁcant ﬁndings could have been due to
chance. Given the former, the validity of the associations
observed in the current meta-analysis would need to be
tested in large, well-designed randomized controlled trials.
The signiﬁcant changes observed for bodyweight and
B M Ia sw e l la sV O 2max in mL·kg−1·min−1 suggest that a
combined aerobic exercise and diet regimen results in
improvements beyond those for lipid and lipoprotein con-
centrations in overweight and obese adults. This reinforces
the investigative team’s perspective that it is highly unlikely
that any pharmacologic intervention will ever be developed
that targets as many risk factors as a combined program of
aerobic exercise and diet. In addition, aerobic exercise and
diet may synergistically improve the eﬀects pharmacologic
therapies such as HMG-CoA reductase inhibitors (statins)
[5]. Finally, the signiﬁcant reductions observed for kilocalo-
ries, total fat, saturated fat, and cholesterol suggest good
adherence to the diﬀerent diet regimens employed.
The small amount of heterogeneity and inconsistency as
well as non-overlapping prediction intervals for BMI, kilo-
calories, and cholesterol intake provide greater credence and
applicability of these outcomes with respect to the eﬀects of
aerobic exercise and diet in overweight and obese adults. For
example, prediction intervals may be more relevant from a
practical perspective since they provide an approximation of
theexpectedtreatmenteﬀectinanewtrial[35].However,the
representativeness of the results for all secondary outcome
analyses may need to be interpreted with caution since they
were only included if data for the primary outcomes (lipids
and lipoproteins) were available.Journal of Obesity 13
Table 5: Metaregression results for changes in lipid and lipoprotein concentrations.
Variable Studies (#) Participants (#) ES (#) β1 (95% CI) RR 2
TC
Age (years) 10 810 12 0.4 (−0.4, 1.3) .33 .11
Gender 6 574 8 −0.57 (−20.9, 19.8) .03 <.01
Initial TC (mg/dL) 11 820 13 0.2 (−0.2, 0.5) .28 .08
Intervention (wks) 11 820 13 0.1 (0.05, 0.2)∗ .74 .55
Δ Body weight (kg) 9 758 10 2.1 (0.8, 3.5)∗ .73 .54
Δ BMI (kg/m2) 7 325 7 10.1 (3.2, 17.0)∗ .83 .69
Δ VO2max(mL·kg−1·min−1) 5 313 7 −0.9 (−3.4, 1.6) .31 .10
Δ Kilocalories 6 389 7 0.02 (−0.03, 0.06) .32 .10
Δ Total fat (%) 7 654 8 0.9 (−0.4, 2.2) .56 .31
Δ Saturated fat (%) 4 304 5 0.4 (−3.5, 4.3) .12 .02
Δ Cholesterol (mg) 4 292 5 −0.1 (−0.3, 0.2) .27 .07
HDL-C
Age (years) 10 810 12 −0.2 (−0.4, 0.1) .41 .17
Gender 6 574 8 −4.0 (−8.9, 0.9) .62 .38
Initial HDL-C (mg/dL) 11 820 13 −0.1 (−0.4, 0.2) .20 .04
Intervention (wks) 11 820 13 0.01 (−0.03, 0.05) .18 .03
Δ Body weight (kg) 10 810 12 −0.5 (−1.0, 0.1) .52 .27
Δ BMI (kg/m2) 7 325 7 0.7 (−1.9, 3.4) .25 .06
Δ VO2max(mL·kg−1·min−1) 4 313 6 0.9 (0.2, 1.5)∗ .75 .56
Δ Kilocalories 6 389 7 −0.02 (−.04, −0.001)∗ .73 .53
Δ Total fat (%) 7 654 8 −0.2 (−0.8, 0.4) .25 .06
Δ Saturated fat (%) 4 304 5 0.6 (−1.6, 2.8) .44 .19
Δ Cholesterol (mg) 4 292 5 −0.05 (−0.1, 0.03) .54 .29
TC:HDL-C
Age (years) 6 383 8 0.02 (−0.02, 0.06) .30 .09
Gender 3 252 5 0.9 (0.5, 1.2)∗ .93 .87
Initial TC:HDL (mg/dL) 4 180 5 −0.9 (−1.6, −0.1)∗ .77 .60
Intervention (wks) 6 383 8 −0.01, (−0.03, 0.01) .28 .08
Δ Body weight (kg) 6 383 8 0.1 (0.1, 0.2)∗ .81 .66
Δ BMI (kg/m2) 4 175 4 0.1 (−0.2, 0.5) .81 .66
Δ VO2max(mL·kg−1·min−1) 2 208 4 −0.2 (−0.9, 0.4) .38 .14
Δ Kilocalories 4 292 5 0.005 (0.002,0.007)∗ .92 .85
Δ Total fat (%) 4 292 5 0.01 (−0.02, 0.1) .74 .54
Δ Saturated fat (%) 3 261 4 0.1 (−0.2, 0.4) ..51 .26
Δ Cholesterol (mg) 4 292 5 −0.0002 (−0.002, 0.002) .12 .02
LDL-C
Age (years) 9 773 11 0.4 (−0.1, 1.0) .43 .18
Gender 4 262 6 3.2 (−10.5, 17.0) .21 .04
Initial LDL-C (mg/dL) 10 783 12 0.3 (−0.02, 0.52) .49 .24
Intervention (wks) 10 783 12 0.06 (0.01, 0.12)∗ .58 .34
Δ Body weight (kg) 9 773 11 1.4 (0.5, 2.4)∗ .67 .45
Δ BMI (kg/m2) 6 290 6 8.6 (2.5, 14.6)∗ .81 .66
Δ VO2max(mL·kg−1·min−1) 4 313 6 −1.1 (−3.0, 0.8) .46 .21
Δ Kilocalories 5 355 6 0.02 (−0.02, 0.07) .50 .25
Δ Total fat (%) 6 620 7 0.5 (−0.6, 1.5) .39 .15
Δ Saturated fat (%) 4 304 5 0.2 (−2.7, 3.2) .09 .01
Δ Cholesterol (mg) 4 292 5 −0.004 (−0.2, 0.2) .03 >.0114 Journal of Obesity
Table 5: Continued.
Variable Studies (#) Participants (#) ES (#) β1 (95% CI) RR 2
TG
Age (years) 10 810 12 1.5 (0.3, 2.7)∗ 0.53 0.28
Gender 6 574 8 6.2 (−21.7, 34.0) 0.13 0.02
Initial TG (mg/dL) 10 777 12 −0.3 (−0.6, −0.1)∗ 0.62 0.38
Intervention (wks) 11 820 13 0.1 (−0.1, 0.2) 0.17 0.03
Δ Body weight (kg) 10 810 12 3.2 (1.1, 5.4)∗ 0.59 0.35
Δ BMI (kg/m2) 7 325 7 0.2 (−21.2, 21.6) .01 <.001
Δ VO2max(mL·kg−1·min−1) 4 313 6 −3.1 (−7.3, 1.2) .49 .24
Δ Kilocalories 6 389 7 −0.02 (−0.1, 0.1) .18 .03
Δ Total fat (%) 6 620 7 1.5 (−0.4, 3.4) .57 .33
Δ Saturated fat (%) 4 304 5 −2.7 (−8.5, 3.0) .51 .26
Δ Cholesterol (mg) 4 292 5 −0.1 (−0.2, 0.4) .39 .15
Notes. ES, eﬀect sizes; #, number for which data were available; Δ, ES change for outcome; β1 (95% CI), slope and 95% conﬁdence interval; ∗,s t a t i s t i c a l l y
signiﬁcant.
The overall reporting and conduct of randomized
controlled trials on this topic could be improved. First,
information on study design characteristics, including allo-
cation concealment, incomplete data (dropouts, reasons for
dropping out, adverse events), and incomplete outcome
reporting should be provided. For incomplete outcome
reporting, the inclusion of the study identiﬁcation protocol
number would be especially helpful to readers. In addition,
since part of the intervention includes exercise, only those
participants not engaged in a regular exercise program prior
to enrollment should be included since prior exercise may
diminish the eﬀects of the intervention. Furthermore, all of
the studies used a per-protocol approach in the analysis of
their data. Given the former, the investigative team suggests
that future studies report data using both the per-protocol
and intention-to-treat approach. Second, the reporting of
selected participant characteristics could be improved. This
includes data on race/ethnicity, medication use before and
during the intervention, cigarette smoking, and alcohol
consumption, as well as any changes in physical activity,
void of the exercise intervention, which occurred during
the study. Third, in order to examine dose-response eﬀects,
additional information regarding the aerobic exercise and
diet intervention should be provided. For aerobic exercise,
data on the duration and intensity of the intervention
as well as compliance to the exercise protocol should be
provided. In addition, the provision of data on energy
expenditure is also recommended. With respect to the diet
intervention,completedatashouldbeprovidedontheintake
of kilocalories, protein, total fat, saturated fat, transfat, and
cholesterol. Fourth, additional lipid assessment data that
includes the number of hours in which subjects refrained
from exercise prior to lipid testing, season(s) in which lipids
were assessed and whether assessment of LDL-C occurred
usingthedirectorindirectmethodshouldbeincluded.Fifth,
since non-HDL-C has been shown to be a better predictor
of cardiovascular morbidity and mortality than LDL-C [42,
43], the calculation of non-HDL-C from TC and HDL-C,
including dispersion statistics is recommended. Given their
potential association with changes in lipid and lipoprotein
concentrations, data on percent body fat as well as lean body
mass would also be helpful.
Finally, the primary purpose of this important meta-
analysis was to focus on the combined versus independent
eﬀects of aerobic exercise and diet on lipids and lipoproteins
in overweight and obese adults. The rationale for this
approach was based on the fact that both are recommended
in tandem for improving the lipid-lipoprotein proﬁle of
adults [5]. Given this study design, we were unable to
determine the independent eﬀects of each on the lipid-
lipoprotein proﬁle. Therefore, future meta-analytic research
should examine the independent eﬀects of aerobic exercise
and diet for improving the lipid-lipoprotein proﬁle of
overweight and obese adults.
In conclusion, the overall results of this study suggest
that a combined program of aerobic exercise and diet is
associated with improvements in TC, LDL-C, TC:HDL-C
and TG, but Not HDL-C, in overweight and obese adults.
However, additional, well-designed randomized controlled
trials on this topic are needed.
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